by Mat Dirjish
Digital-health company Eko unveils SENSORA, a cardiac-disease-detection platform it describes as an enterprise-grade digital stethoscope that enables non-invasive heart disease detection. The platform currently employs artificial intelligence (AI) technology that objectively identifies structural heart murmurs, a sign of valvular heart disease. It also includes the company’s Care Pathway Analytics software that provides downstream visibility and metrics of a patient’s path through a healthcare system.
Eko’s SENSORA operates on a tablet that features 3M’s Littmann CORE digital stethoscope. The company claims the tablet combines current machine-learning technology with the stethoscope. Its FDA-cleared structural murmur detection helps to accurately and consistently identify valvular heart disease (VHD) in patients during a routine visit with their primary care physician. A life-threatening condition, VHD affects more than eight million Americans and can lead to heart failure, stroke, blood clots, and, obviously, death if undetected and untreated.
Allegedly, older adults have a one in 10 chance of developing VHD, but more than half of clinically-significant VHD goes undetected. Eko claims, “A primary care physician using SENSORA for structural murmur detection more than doubles their likelihood of detecting significant VHD.”
Additionally, the platform’s Care Pathway Analytics follows patients with identified structural murmurs, providing downstream visibility into patient flows, clinical outcomes, and patient economics. Care Pathway Analytics assists critical decision-making by identifying care gaps that are transformable into higher operational efficiencies including lower delays in delivery of care, length of stay, and readmission rates.
Dr. John Chorba, Assistant Professor in Residence, Division of Cardiology, Zuckerberg San Francisco General Hospital and Department of Medicine, University of California San Francisco, said, “The primary care setting is a patient’s first line of defense for identifying and diagnosing heart disease. However, we know from clinical evidence that detection rates are low. The SENSORA platform promises to better serve patients by increasing the accuracy and consistency of structural murmur identification and improving patients’ lives by getting them into treatment earlier.”
Healthcare providers and systems administrators wishing to learn more about SENSORA for structural murmur detection can visit Eko’s booth #1407 at the ACC 2023 Annual Scientific Session & Expo from March 4 to 6, 2023. For even deeper data, visit the Eko VHD overview.
| firstname.lastname@example.org | 1-516-422-1431 |